By Fineline Cube 
Nona Biosciences, a subsidiary of HBM Holdings Ltd (HKG: 2142), announced a licensing agreement with Visterra, Inc. The deal grants Visterra access to Nona’s HCAb Harbour Mice technology platform, aimed at advancing the development of innovative biologic treatments for immune-mediated and autoimmune diseases.
HCAb Harbour Mice Platform
The HCAb Harbour Mice platform enables the generation of fully human heavy-chain-only antibodies (HCAbs). These antibodies are characterized by low immunogenicity and high flexibility. The platform has been clinically validated and is well-regarded among global partners.
Collaboration Benefits
This collaboration equips Visterra with the tools to expand its antibody drug pipeline and accelerate the development of transformative therapeutics. Nona Bio specializes in integrated antibody drug discovery and preclinical development services, while Visterra focuses on pioneering antibody therapies for immune-mediated kidney diseases and other challenging conditions.-Fineline Info & Tech